Case presented by Dr Polkinghorn

Slides:

Advertisements

Similar presentations

David Kerr University of Oxford Oxford, UK

Advertisements

PreOP XRT: Oral fluoropyrimidines in randomized trials

A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer CCOP Investigators’

A Phase III Trial Comparing FULV to FULV + Oxaliplatin in Stage II or III Carcinoma of the Colon: Results of NSABP-C-07 Norman Wolmark, MD Colorectal Cancer.

D. Haller, 1 J. Cassidy, 2 J. Tabernero, 3 J. Maroun, 4 F. de Braud, 5 T. Price, 6 E. Van Cutsem, 7 M. Hill, 8 F. Gilberg, 9 H-J. Schmoll 10 1 University.

ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.

DEBATE: What is the Optimal Strategy for Liver Only Metastatic Colon Cancer? Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center.

Academic & Community Cancer Research United (ACCRU) Scientific Achievements.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Lars Påhlman Dept. Surgery, Colorectal unit, University Hospital, Uppsala, Sweden How to handle peritoneal carcinomatosis found at laparotomy.

N ational S urgical A djuvant B reast and B owel P roject.

1 Stage III Colon Cancer What Works? Thierry André, MD Medical Oncology Departement, Hôpital Saint Antoine, APHP, Paris, France and University Pierre et.

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.

Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Morganstein (Prof Van Cutsem) 78 yo woman with Stage IV GE adenocarcinoma.

ESMO/ECCO Presidential Session III

Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up.

Discussion abstracts Alberto Sobrero MD Ospedale San Martino Genoa, Italy.

Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Schwartz 44 yo woman with 4 mo hx of abdominal pain –Imaging = pancreatic.

Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.

A Report from ASCO-GI 2008 and ASCO 2007 Up-to-Date Review of the Treatment of Adjuvant Colorectal Cancer Axel Grothey, MD Professor of Oncology Mayo Clinic.

Patterns of Care in Medical Oncology Adjuvant Systemic Therapy for Colon Cancer.

Bevacizumab (Bev) in combination with XELOX or FOLFOX-4: updated efficacy results from XELOX-1 / NO16966, a randomized phase III trial in first-line metastatic.

Better Regimens & Predictive Markers For Advanced Esophagogastric Cancer? Peter C. Enzinger, M.D. Dana-Farber Cancer Institute/Harvard Medical School.

Poster #382 XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated.

Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.

Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact.

This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.

NSABP C08 adjuvant colon cancer Best of ASCO, Beirut, July 2009 Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium.

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

Outcomes Following Adjuvant 5-FU based Treatment (AT) for Colon Cancer vs Impact on Recurrence Rate, Time from Recurrence to Death.

T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

Xeloda for the adjuvant treatment of stage III colon cancer Chris Twelves University of Leeds and Bradford NHS Trust UK.

Best of ASCO – Colorectal & Pancreatic Cancers Best of ASCO Colorectal & Pancreatic Cancers Ali Shamseddine, MD Professor of Medicine Head of Hematology/Oncology.

A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.

Individualizing Adjuvant Therapy on the Basis of Molecular Markers Charles S. Fuchs, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA.

Which Adjuvant Systemic Treatments Would Medical Oncologists Wish to Receive If They Had Colon Cancer? A Survey of 150 Physicians N Love, MD 1 ; NJ Meropol,

Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?

XELOX vs. FOLFOX4: survival and response results from XELOX-1 / NO16966, a randomized phase III trial of first-line treatment for patients with metastatic.

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

NSABP Overall Survival and Updated Disease-Free Survival Results of the NSABP C-08 Trial Assessing Bevacizumab in Stage II & III Colon Cancer CJ Allegra,

Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast.

Tolerability of fluoropyrimidines differs by region Daniel G. Haller on behalf of: Cassidy J, Clarke S, Cunningham D, Van Cutsem E Hoff P, Rothenberg M,

Adjuvant Therapy of Colon Cancer: Where are we now ? Leonard Saltz, MD Memorial Sloan Kettering Cancer Center New York, NY.

Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.

Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.

A three-arm randomized phase III trial of FOLFOX4 vs FOLFOX4 + bevacizumab vs XELOX + bevacizumab in the adjuvant treatment of patients with stage III.

Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

A multinational, randomized phase III study of bevacizumab with FOLFOX4 or XELOX vs. FOLFOX4 alone as adjuvant treatment for colon cancer: Results and.

Adjuvant therapy in colon cancer

Neoadjuvant & Adjuvant Chemotherapy for Hepatic Colorectal Metastases : When to use it ? SURGERY FIRST May 30 , 2009.

How to treat a patient with stage III Colon Cancer in 2013

Case presented by Dr Schwartz

Which Adjuvant Systemic Treatments Would Medical Oncologists Wish to Receive If They Had Colon Cancer? A Survey of 150 Physicians N Love, MD1; NJ Meropol,

National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Case presented by Dr Moriarty

NSABP Protocol C-08 Ming He MD.

What is the most appropriate therapy for a 50 year old patient with T3N+ rectal cancer and isolated resectable liver metastases? Systemic chemotherapy->chemoradiation->surgery.

Colon Cancer Stages I-III

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Oesophageal and Gastric cancer: neo-adjuvant therapy

Jordan Berlin Co-Director, GI Oncology Program

National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00.

First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.

A phase III trial assessing bevacizumab in stage II and III

Discussion on Abstracts 362, 363, 364, 365, and 366 or…We still have a lot to learn about colorectal cancer Johanna Bendell, MD Director, GI Oncology Research.

1Cancer Research UK, Glasgow, United Kingdom

Presentation transcript:

Case presented by Dr Polkinghorn 65 yo woman with obstructive colon CA  emergency diverting colostomy 7/2009: Found to have synch but isolated liver mets FOLFOX/bevacizumab with significant response  some RFA of liver mets + reversal of colostomy Postoperative complications (liver abscess requiring drainage) ? Recurrent vs residual lesion in liver After healing, restarted on capecitabine/bevacizumab

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 Allegra CJ et al. J Clin Oncol 2011; 1(29); 11-16 Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next? Eric Van Cutsem et al. J Clin Oncol 2011; 1(29); 1-4

AVANT: Results from a Randomized, Three-Arm Multinational Phase III Study to Investigate Bevacizumab with Either XELOX or FOLFOX4 vs FOLFOX4 Alone as Adjuvant Treatment for Colon Cancer De Gramont A et al. Proc GI Cancers Symposium 2011;Abstract 362.

Case presented by Dr Polkinghorn 65 yo woman with obstructive colon CA  emergency diverting colostomy 7/2009: Found to have synch but isolated liver mets FOLFOX/bevacizumab with significant response  some RFA of liver mets + reversal of colostomy Postoperative complications (liver abscess requiring drainage) ? Recurrent vs residual lesion in liver After healing, restarted on capecitabine/bevacizumab 4